CJC-1295 No DAC Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Limited early-phase pharmacodynamic data.

Animal evidence: Preclinical GHRH-receptor studies.

Introduction & Mechanism of Action

Shorter-acting GHRH analog variant studied for growth-hormone pulse research.

GHRH(1-29) analog without the drug-affinity complex, giving it a short half-life that better mimics the body's natural pulsatile GHRH release pattern, at the cost of requiring more frequent dosing.

Receptors/targets: GHRH receptor

Areas of Research Interest

• Growth-hormone pulse research
• Recovery studies

Benefits Reported in Research

• Growth-hormone pulse research
• Recovery studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 100–300 mcg

Reported frequency: 1–2× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on CJC-1295 No DAC reports administration at 100–300 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Flushing
• Injection-site reaction
• Headache

Contraindications

• Active malignancy (theoretical concern)
• Pregnancy

Drug interactions

• Ghrelin-receptor agonists (e.g. Ipamorelin) — commonly combined, marketed together as CJC no-DAC / Ipamorelin

Safety

• Frequent dosing burden
• Injection-site reactions

Shorter-acting than the DAC variant, requiring more frequent dosing; human evidence remains limited.

Expected Results & Comparison

Shorter-acting than the DAC variant, requiring more frequent dosing but producing a GH-release pattern closer to natural pulsatility — this is the version most commonly paired with Ipamorelin as a combination product.

References

Continue